Cat’s Whiskers — Benefits Deep Dive

Cat’s whiskers is one of the most-consumed medicinal teas in Southeast Asia. It is misai kucing in Malaysia, kumis kucing in Indonesia, râu mèo in Vietnam, yaa nuat maeo in Thailand, and java tea on European pharmacy shelves — every one of those names describing the long pale stamens that shoot out past the flower like whiskers. Almost everywhere it grows, people drink it for the same thing: difficult urination, gravel and stones, swelling, gout. It is drunk casually, daily, and often for years.

The botany is worth fixing before anything else, because it fragments the evidence. The currently accepted name is Orthosiphon aristatus, which is what the European monograph uses. The older synonym Orthosiphon stamineus is still the commonest name in the pharmacology literature, and papers also appear under Orthosiphon grandiflorus (the Thai kidney-stone trial), Orthosiphon spicatus and Clerodendranthus spicatus. Searching one name silently misses most of the field, so every study cited across this leg has its binomial named — both to keep the borrowing visible and so you can find it again. The constituents that matter are sinensetin and eupatorin (methylated flavones, used as analytical markers), rosmarinic acid and related caffeic-acid depsides, the genus-specific orthosiphol diterpenes, and — the single most abundant characteristic constituent — potassium.

These four pages exist because the popular account of this herb and its actual file point in different directions. The herb is famous for the kidney and holds a European licence for urinary flushing, yet its best single-herb human trial is about cancer-related fatigue; the compounds on its label are the ones least likely to dissolve in the cup; its two human blood-pressure trials tested products containing three other active ingredients; and its formal contraindication names precisely the group it is marketed to. None of that makes it a bad plant. It makes it a plant whose claims need reading carefully, which is what follows.

Table of Contents

1. Deep-Dive Articles
2. How to Read This Leg
3. The Five Things Worth Knowing
4. Evidence Ledger at a Glance
5. Who Should Not Drink This
6. Key Research
7. External Resources
8. Connections

Deep-Dive Articles

How to Read This Leg

Four habits run through all four pages, and knowing them makes the pages faster to use.

1. Every claim carries an evidence tier — regulatory, randomised human trial, animal, in vitro, or traditional use only — stated at the claim rather than once in a preamble. A reader arriving mid-page, or quoting one line, should carry the label with them.
2. Borrowed evidence is labelled where it is borrowed. A result obtained with an ethanolic extract is not a result about a tea; a result from a four-plant formula is not a result about one plant; a result for rosmarinic acid is not a result about a species that shares the compound with rosemary and lemon balm. Each of these appears in this herb’s file, and each is flagged at the citation.
3. Absent and negative are kept apart. An untested claim and a claim that failed a trial are different verdicts, and collapsing them flatters the untested one while unfairly damning the tested one. Cat’s whiskers is almost entirely in the absent column. Uva ursi, its nearest neighbour, has a genuinely negative one.
4. Numbers we cannot stand behind are refused out loud. Where a figure would require an input we cannot verify — a drug-to-extract ratio, a milligram per cup, a urinary concentration — the pages say so and give a range or nothing. That refusal is stated rather than hidden, because a confident wrong number does more damage than an honest gap.

All four pages also cite only through PubMed topic searches, with each paper’s title, journal and year given in the prose. A search link cannot silently resolve to the wrong paper the way a bare identifier can.

The Five Things Worth Knowing

If you read nothing else in this leg:

1. The European licence is a traditional-use registration, and that is a legal category rather than a scientific verdict. It requires thirty years of documented use, plausibility and safety — and explicitly no efficacy data. The monograph’s “well-established use” column, the one that needs clinical evidence, is empty. Europe has said this is plausible and apparently safe. It has not said it works.
2. You cannot tell whether it is working, and neither can anyone else. The licensed regimen delivers 300–600 mL of extra fluid a day plus an instruction to drink more. Increased urination during use is guaranteed by the vehicle. That single fact disqualifies every testimonial ever offered for a diuretic tea.
3. The tea and the capsule are not the same drug. The marker flavones are polymethoxylated, which makes them lipophilic and poorly water-soluble, so they extract well into ethanol and badly into a cup. The stronger the flavone pharmacology looks, the weaker the case for the traditional infusion.
4. Its best human evidence is off-target. A phase II randomised, double-blind, placebo-controlled trial of a rosmarinic-acid-rich single-herb extract reduced cancer-related fatigue in patients on chemotherapy. That is the highest-quality result this plant has, and it is for an indication nobody buys it for, at 3 g of concentrated extract a day, standardised to a different compound from the one on the pharmacopoeial label.
5. Its formal contraindication names the people it is marketed to. The monograph contraindicates it in conditions requiring reduced fluid intake, naming severe cardiac or renal disease. The shelf sells it as kidney support. Both statements are about the same reader.

Evidence Ledger at a Glance

Ranked by strength of evidence rather than by fame, which puts the popular claims low and the safety facts high.

1. Randomised, double-blind, placebo-controlled, single herb — positive but phase II and unreplicated. Reduced cancer-related fatigue with a standardised rosmarinic-acid-rich extract, 3 g/day, in 110 patients on chemotherapy.
2. Randomised human trials — positive but uninterpretable for this herb. Two Italian trials of four-ingredient supplements reported small blood-pressure and metabolic effects; magnesium, hawthorn and hibiscus were also in the capsule, and hibiscus and magnesium have their own single-agent meta-analyses.
3. One small randomised comparison, underpowered. Java tea versus potassium citrate in 48 Thai stone-formers found similar stone shrinkage — with no placebo arm and only enough power to detect a gap three times larger than the one observed.
4. Regulatory. A European traditional-use registration for increasing urine volume to flush the urinary tract, as an adjuvant, in minor complaints, in adults, for up to two weeks. Documented long use, not demonstrated efficacy.
5. Animal — positive and negative in the same file. A 50% ethanolic extract raised rat urine volume about 1.3-fold against furosemide’s 2.5-fold; a 70% ethanolic extract raised it not at all. Improved uric acid excretion in the same review.
6. Ex vivo and animal. Three polymethoxyflavones produced synergistic vasodilation in aortic rings and lowered blood pressure in hypertensive rats.
7. In vitro only. Stone dissolution in a beaker; antibacterial activity in culture; antioxidant and anti-inflammatory activity in cell systems.
8. Preliminary, and thrice-removed. A four-herb combination reduced colonisation and biofilm on catheter material — wrong number of plants, wrong surface, wrong endpoint for the claim it supports.
9. Absent, not refuted. Any trial of the herb for urinary tract infection, gout, blood sugar, stone prevention against placebo, or blood pressure as a single agent. Any human pharmacokinetics. Any study in kidney impairment. Any tea-versus-extract comparison.
10. Traditional use only. Kidney cleansing, gravel, difficult urination, oedema, gout.
11. Safety facts, which are among the best-established things about this plant. A long everyday record with no known undesirable effects and no reported overdose; a formal contraindication in severe cardiac and renal disease; a two-week limit; not recommended in pregnancy, breastfeeding or under 18; and genotoxicity, carcinogenicity and reproductive toxicity testing never performed.

Who Should Not Drink This

The short version of the safety page, which explains each of these properly.

• Anyone advised to restrict fluid — the formal contraindication, naming severe cardiac or renal disease.
• Chronic kidney disease of any stage, without agreement from the clinician who manages it, and with potassium and kidney function checked if you proceed.
• Anyone on a counted potassium budget, or taking potassium supplements or potassium-chloride salt substitutes.
• Anyone taking prescription diuretics, ACE inhibitors, ARBs, spironolactone or similar, or lithium — not because an interaction is documented, but because no interaction study has ever been done.
• Pregnancy and breastfeeding, and anyone under 18 — on absent data rather than demonstrated harm.
• Anyone with fever, painful urination, spasms, visible blood in the urine or flank pain — the monograph’s own stop-and-seek-care list.
• Anyone using it in place of prescribed treatment for infection, gout, high blood pressure or stone prevention.

Key Research

Grouped by theme. Every entry gives the paper’s title, journal and year in prose and links to a PubMed topic search, so a link can never resolve to the wrong record. Regulatory documents are named rather than cited to a database entry.

1. The regulatory file, and what it does and does not establish

1. European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium, with its accompanying assessment report, from the European Medicines Agency’s Committee on Herbal Medicinal Products. The source of the approved indication, the dose table, the contraindications, the “none known” adverse-effect statement, the ~3% potassium figure, and the explicit statement that genotoxicity, carcinogenicity and reproductive toxicity testing were not performed.
2. Background on what a traditional-use registration is and is not — PubMed: the European traditional herbal medicinal products framework.
3. Topic search covering the whole plant under both principal names — Orthosiphon aristatus and Orthosiphon stamineus. Run both.

2. Diuresis, urine flow and kidney stones

1. A long-term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment. Southeast Asian Journal of Tropical Medicine and Public Health, 2001. The only human stone trial. PubMed search
2. An in vitro study of Orthosiphon stamineus (Misai Kucing) standardized water extract as a chemolytic agent in urolithiasis. Journal of Pharmacy and Bioallied Sciences. Stone dissolution in a beaker. PubMed search
3. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. Journal of Urology, 1996. The evidence behind the fluid target — and the reason a pleasant drink has a genuine, if indirect, role. PubMed search
4. Medical management of kidney stones: AUA guideline. Journal of Urology. Where citrate and thiazides belong, and on what basis. PubMed search
5. Herbal medicines as diuretics: a review of the scientific evidence. Journal of Ethnopharmacology. The state of the whole field. PubMed search
6. Topic search — Orthosiphon and diuresis and Orthosiphon and urolithiasis.

3. Urinary tract, infection and the comparator trials

1. Solidago, orthosiphon, birch and cranberry extracts can decrease microbial colonization and biofilm development in indwelling urinary catheter: a microbiologic and ultrastructural pilot study. World Journal of Urology, 2014. The four-herb catheter pilot, and the most-cited — and most misquoted — item in this plant’s antibacterial file. PubMed search
2. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection, 2019. The placebo-controlled trial on the neighbouring herb, and the reason “absent” and “negative” must be kept apart. PubMed search
3. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clinical Microbiology and Infection, 2021 (REGATTA). PubMed search
4. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Internal Medicine, 2018. Flushing, demonstrated with plain water. PubMed search
5. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ, 2022 (ALTAR). What a genuine antibiotic-sparing option looks like when one works. PubMed search
6. Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews. PubMed search

4. Metabolic, vascular and the single-herb trial

1. A phase II randomized, double-blind, placebo-controlled study of Nuvastatic (C50SEW505OESA), a standardized rosmarinic acid-rich polymolecular botanical extract formulation to reduce cancer-related fatigue in patients with solid tumors. Supportive Care in Cancer, 2024. The best single-herb evidence this plant has. PubMed search
2. Effect of dietary supplementation with Diuripres on blood pressure, vascular health, and metabolic parameters in individuals with high-normal blood pressure or stage I hypertension: the CONDOR randomized clinical study. Phytotherapy Research, 2023. Four ingredients, one of them orthosiphon. PubMed search
3. Effect of a combined nutraceutical containing Orthosiphon stamineus on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial. Complementary Therapies in Clinical Practice, 2012. PubMed search
4. Mechanistic insights into the synergistic vasodilatory actions of eupatorin, sinensetin, and 3′-hydroxy-5,6,7,4′-tetramethoxyflavone in ex vivo aortic ring model and their antihypertensive efficacy in in vivo rat model. Hypertension Research, 2025. PubMed search
5. Elucidating the therapeutic mechanism of Orthosiphon aristatus in hyperuricemic nephropathy: an integrated microbiome–metabolomics approach. Journal of Ethnopharmacology. Animal model. PubMed search
6. The named alternative explanations for the combination-trial results — hibiscus and blood pressure and magnesium and blood pressure.

5. Chemistry, pharmacokinetics, identity and safety

1. Analysis of the chemical constituents and their metabolites in Orthosiphon stamineus Benth. via UHPLC-Q Exactive Orbitrap-HRMS and AFADESI-MSI techniques. PLoS One, 2024. The modern constituent inventory. PubMed search
2. Gut microbiota of pigs metabolizes extracts of Filipendula ulmaria and Orthosiphon aristatus — herbal remedies used in urinary tract disorders. Planta Medica, 2022. Why the compounds absorbed are not the compounds on the certificate. PubMed search
3. Topic search — polymethoxylated flavone solubility and bioavailability. The chemistry behind the tea-versus-extract argument.
4. Topic search — DNA barcoding for herbal product authentication. Why a sinensetin assay is a potency check, not an identity check.
5. Topic search — Orthosiphon stamineus toxicity and subchronic safety. The whole toxicology file, which is smaller than the pharmacology file.
6. Topic search — hyperkalaemia in chronic kidney disease on renin-angiotensin blockade. Why an uncounted potassium source matters in the group most likely to drink this.

External Resources

• European Medicines Agency — Herbal medicinal products. The home of the EU herbal monographs and their assessment reports, including the one for Orthosiphonis folium, and the clearest official explanation of what a traditional-use registration means.
• National Center for Complementary and Integrative Health. Independent, plainly written summaries of herb evidence and safety, from the US National Institutes of Health.
• National Institute of Diabetes and Digestive and Kidney Diseases. Patient-level information on kidney disease, kidney stones and urinary conditions.
• National Kidney Foundation. Practical guidance on potassium in the diet, stone prevention and understanding kidney test results.
• KDIGO. The international clinical practice guidelines used to stage and manage chronic kidney disease.
• American Urological Association. Source of the guidelines on medical management of kidney stones referred to throughout this leg.
• Plants of the World Online (Royal Botanic Gardens, Kew). The authority for checking which Orthosiphon names are accepted and which are synonyms — useful before believing any label.
• PubMed. Every citation on these pages is a live search here; run the binomials separately, because the literature is split across them.

Connections

• All Herbs
• Cat’s Whiskers / Java Tea — the main topic page: botany, names, the full monograph, constituents, forms and dosage.
• Diuretic and Kidney Stone Claims — the core claim, with the arithmetic printed.
• Urinary Tract Complaints — what flushing licenses, and the red flags.
• Metabolic, Blood Pressure and Other Research — the modern research file, sorted.
• Kidney Cautions, Interactions and Safety — potassium, prescriptions and product identity.
• Uva Ursi Benefits — the urinary herb that was trialled, and the calibration point for this whole leg.
• Uva Ursi: What the Trials Found — a genuinely negative result, and the red-flag approach this leg follows.
• Cleavers Benefits — where the water-in-the-cup argument on this site was first worked out.
• Horsetail Benefits — another traditional aquaretic with its own EU registration and its own duration cap.
• Dandelion Benefits — the high-potassium diuretic leaf with the best human measurement in this family.
• Chanca Piedra Benefits — the South American “stone breaker,” the closest parallel in another hemisphere.
• Stinging Nettle Benefits — the same tonic-diuretic reputation, with similarly thin human data.
• Kidney Stones — stone types, workup and what actually prevents recurrence.
• Urinary Tract Infections — why a flushing tea is not a treatment for an infection.
• Kidney Disease — the group this herb is contraindicated in and marketed to.
• Heart Failure — the other named contraindication.
• Gout — a traditional indication with no human evidence and proven drugs available.
• Potassium — the leaf’s most abundant characteristic constituent.
• Kidney Function Tests — the numbers “supports kidney function” never reports.

Back to Table of Contents